Please Wait...

Lost to Follow-Up

Finding Patients Lost to Follow-Up

The ultimate success of any clinical trial depends upon the timely submission of complete and accurate data. When study subjects drop out of your trial, it compromises your data's integrity. Plus, it costs you money and delays your clinical trial endpoint.

Bioclinica's lost to follow-up service, Bioclinica L2FU®, optimizes clinical trial success by greatly reducing the number of patients lost to follow-up and, with them, important data. We locate lost to follow-up clinical trial patients in more than 60 countries worldwide, with the support of a specialized team and a secure online portal to facilitate the encrypted exchange of patient information.

Why Choose Bioclinica L2FU®?

  • Provide vital status on subjects
  • Maintain clinical trial integrity by reducing missing data
  • Comply with FDA, EMEA, and regulatory guidelines or requests
  • Enable a faster clinical trial endpoint
  • Reduce clinical trial costs
  • Comply with GCP guidelines related to information security
  • Maintain full HIPAA compliance for data privacy

ADDITIONAL RESOURCES

Patient Recruitment and Retention

Download Brochure

Alzheimer's Disease

Download Case Study

Pediatric Schizophrenia

Download Case Study

Chronic Pain Study

Download Case Study

RAPSODI Study

Download Case Study

ALLEGRO Study

Download Case Study

The ALFACHIN Study

Download Case Study

Childhood Depression Study

Download Case Study

Nerve Pain Study

Download Case Study

Global Clinical Research

Download Brochure

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (2 days ago)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (3 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (5 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (5 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (5 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (5 days ago)

Latest Blogs: